Accessibility Menu
Kane Biotech logo

Kane Biotech(OTC) KNBIF

Market Cap$4.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-97%
5 Year-86%
1 Year-30%
1 Month+2%
$0.02
+0%
+0.00Today
Kane Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.022026-07-28
Kane Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.38%USD 0.022026-07-17
1 month+2.34%USD 0.022026-06-26
3 month-22.46%USD 0.032026-04-27
Year to date-24.21%USD 0.032025-12-10
1 year-30.48%USD 0.032025-07-24
3 year-69.75%USD 0.072023-07-26
5 year-85.6%USD 0.142021-07-26
Since inception-96.6%USD 0.592011-10-12

Kane Biotech Financials at a Glance

Market Cap

$4.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$58.34K

Net Income (TTM)

-CA$2.22M

EPS (TTM)

-$0.01

P/E Ratio

-2.32

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.02

Volume

900

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.01 - $0.04

Estimated Earnings Date

Aug 27, 2026

KNBIF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kane Biotech

Kane Biotech Inc. is a biotechnology firm focused on the research, development, and commercialization of innovative technologies aimed at preventing and eradicating microbial biofilms. The company offers a diverse range of products, including pet dental care solutions and wound treatment products for both animals and humans.

Products and Services
  • Pet dental care solutions under the StrixNB and bluestem brands
  • DispersinB for treating wounds in animals and humans
  • Alosera shampoos and Aledex coatings for medical devices
Growth Outlook
  • Expansion into new markets is anticipated to drive revenue growth
  • Innovative product development is expected to enhance market competitiveness
  • Strategic partnerships may facilitate broader distribution channels
Financial Highlights
  • Recent quarterly revenue of CAD 43,329 reflects ongoing operational challenges
  • Trailing twelve months (TTM) revenue shows a significant decline compared to previous periods
  • Current ratio of 0.45 indicates potential liquidity concerns
Kane Biotech Inc. operates in a niche market with a focus on addressing microbial biofilms, which pose significant challenges in various sectors, including healthcare and pet care. The company's innovative product lineup positions it well for future growth, particularly as awareness of biofilm-related issues increases. However, recent financial performance indicates challenges, with a notable decline in revenue and liquidity concerns reflected in the current ratio. Investors may find the company's strategic initiatives and product development efforts noteworthy as they navigate the biotechnology landscape.
AI Generated • Jul 4, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert B. Huizinga, PhD

Website

www.kanebiotech.com

Headquarters

Winnipeg, MB R3T 6G2, CA

KNBIF Financials

Key Financial Metrics (TTM)

Gross Margin

-390.49%

Operating Margin

-4487.60%

Net Income Margin

-3785.93%

Return on Equity

277.77%

Return on Capital

-199.79%

Return on Assets

-122.46%

Earnings Yield

-43.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

205.06M

Volume

900

Avg. Volume

10.22K

Financials (TTM)

Gross Profit

-CA$228.65K

Operating Income

-CA$2.63M

EBITDA

-CA$2.50M

Operating Cash Flow

-CA$2.64M

Capital Expenditure

CA$39.95K

Free Cash Flow

-CA$2.60M

Cash & ST Invst.

CA$396.08K

Total Debt

CA$1.92M

Kane Biotech Performance Analysis

Kane Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 120,392-90.6%
20232023-12-31CAD 110,381-8.3%
20242024-12-31CAD 1,518,9321276.1%
20252025-12-31CAD 306,214-79.8%
Kane Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-93.2%
Q32025-09-30-69.6%
Q42025-12-31-352.8%
Q12026-03-31301.6%
Kane Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.02-23.9%
20232023-12-31CAD -0.0318.1%
20242024-12-31CAD -0.02-43.7%
20252025-12-31CAD -0.01-27.3%
Kane Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3074.1%
Q32025-09-30-71.4%
Q42025-12-3119.4%
Q12026-03-31-34.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$43.33K

-89.5%

Gross Profit

-CA$22.96K

-154.1%

Gross Margin

-52.99%

N/A

Market Cap

$4.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$206.70K

N/A

Employees

20

N/A

Net Income

-CA$716.67K

+41.2%

EBITDA

-CA$660.00K

+40.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$396.08K

-19.8%

Total Debt

CA$1.92M

-7.5%

Accounts Receivable

CA$29.46K

-85.6%

Inventory

CA$477.92K

+203.3%

Long Term Debt

CA$640.20K

-59.7%

Short Term Debt

CA$1.28M

+161.7%

Return on Assets

-1.22%

N/A

Return on Invested Capital

3.37%

N/A

Free Cash Flow

-CA$486.90K

+57.6%

Operating Cash Flow

-CA$486.91K

+55.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BVAXFBioVaxys Technology Corp.
$0.11+0.00%
BUDZWEED, Inc.
$0.02-9.50%
PMEDFQscreen Ai Inc.
$0.03+0.00%
BIXTBioxytran, Inc.
$0.02+7.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About KNBIF

What is the current price of Kane Biotech?

Kane Biotech is trading at $0.02 per share.

What is the 52-week range for Kane Biotech?

Over the past 52 weeks, Kane Biotech has traded between $0.01 and $0.04.

How much debt does Kane Biotech have?

As of the most recent reporting period, Kane Biotech reported total debt of CA$1.37M.

How much cash does Kane Biotech have on hand?

Kane Biotech reported CA$283.08K in cash and cash equivalents in its most recent financial results.

What is Kane Biotech’s dividend yield?

Kane Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services